Search for topics, articles, videos, research, etc...
Hit enter to search or ESC to close
Are you looking for:
Research News
Donate Now
Parkinson's Research

Research News

Read the latest developments, reporting and analysis from the world of Parkinson's research, including progress made in studies, tools and collaborations funded by The Michael J. Fox Foundation.
  • Global

    New Estimate Suggests 25 Million People with Parkinson’s by 2050

    The Michael J. Fox Foundation explores challenges in determining how many people have Parkinson’s disease now and will in the future — and why this matters. Learn more.
    Learn more
  • Two people wearing sneakers walking.

    New Gait Assessment Protocol Aims at Standardizing Data Collection and Improving Clinical Trials

    The Gait Advisors Leading Outcomes for Parkinson’s (GALOP) committee for The Michael J. Fox Foundation recommends a standardized, sensitive protocol for assessing gait. Learn more.
    Learn more
  • Researcher in a lab

    What We Fund: $86 Million to Refine Our Understanding of Parkinson’s

    Two months of research grants total $86 million across 127 projects.
    Learn more
  • Test tubes in a research lab.

    Exenatide, a GLP-1 Drug, Shows No Impact on Parkinson’s Symptoms

    In a clinical trial, exenatide, a GLP-1 receptor agonist, showed no impact on slowing the progression of Parkinson’s disease or improving symptoms.
    Learn more
  • Patient speaks with doctor in an office

    Second Under-the-Skin Infusion for Parkinson’s Earns FDA Approval

    The U.S. Food and Drug Administration has approved Onapgo, a continuous, under-the-skin infusion of apomorphine for the treatment of Parkinson’s motor symptoms.
    Learn more
  • Test tubes in a research lab.

    News in Context: Mixed Results from Two Experimental Drugs Targeting Alpha-Synuclein

    This week, pharmaceutical companies reported results from two Phase II clinical trials of two respective experimental drugs designed to slow the progression of PD by targeting alpha-synuclein.
    Learn more
  • Allie Vaiana, PhD

    Allie Vaiana, PhD, Searches for Better Ways to Target Parkinson’s Symptoms

    Allie Vaiana, PhD, is a senior scientific portfolio manager on MJFF’s translational research team. In our researcher spotlight series, we learn more about Allie’s work.
    Learn more
Close-up portrait

Join the Study that's Changing Everything

The Parkinson's Progression Markers Initiative is changing how patients, families, doctors and scientists think about brain disease. Now it needs you.

Get Started
Michael J. Fox in blue sweater posing for the camera.

Patients First

Our Foundation exists for one reason: to speed breakthroughs patients can feel in their everyday lives.

Read Our Promise
"The question most frequently asked of us is: 'How close are we to a cure for Parkinson’s disease?' With over $800 million in Parkinson's research funded to date, the simplest answer is: closer than ever."
Todd Sherer, PhD
Todd Sherer, PhD Chief Mission Officer
We use cookies to ensure that you get the best experience. By continuing to use this website, you indicate that you have read our Terms of Service and Privacy Policy.